|
|
|
Prospectus Supplement No. 16
(to
Prospectus dated May 30, 2013)
|
|
Filed pursuant to Rule 424 (b)(4)
Registration No. 333-187508
|
125,000 Shares of Series A Convertible Preferred Stock
12,500,000 Shares of Common Stock Underlying the Preferred Stock
Warrants to Purchase up to 6,250,000 Shares of Common Stock and
6,250,000 Shares of Common Stock Underlying the Warrants
ARCA biopharma, Inc.
This prospectus supplement supplements the prospectus dated May 30, 2013 (the Prospectus), as supplemented by that certain
Prospectus Supplement No. 1 dated July 17, 2013 (Supplement No. 1), by that certain Prospectus Supplement No. 2 dated July 19, 2013 (Supplement No. 2), by that certain Prospectus Supplement
No. 3 dated July 24, 2013 (Supplement No. 3), by that certain Prospectus Supplement No. 4 dated July 30, 2013 (Supplement No. 4), by that certain Prospectus Supplement No. 5 dated
August 6, 2013 (Supplement No. 5), by that certain Prospectus Supplement No. 6 dated September 4, 2013 (Supplement No. 6), by that certain Prospectus Supplement No. 7 dated September 23,
2013 (Supplement No. 7), by that certain Prospectus Supplement No. 8 dated October 29, 2013 (Supplement No. 8), by that certain Prospectus Supplement No. 9 dated November 6, 2013
(Supplement No. 9), by that certain Prospectus Supplement No. 10 dated November 13, 2013 (Supplement No. 10), by that certain Prospectus Supplement No. 11 dated November 21, 2013
(Supplement No. 11), by that certain Prospectus Supplement No. 12 dated December 5, 2013 (Supplement No. 12), by that certain Prospectus Supplement No. 13 dated January 8, 2014 (Supplement
No. 13), by that certain Prospectus Supplement No. 14 dated February 10, 2014 (Supplement No. 14), and by that certain Prospectus Supplement No. 15 dated February 12, 2014 (Supplement
No. 15, and together with Supplement No. 1, Supplement No. 2, Supplement No. 3, Supplement No. 4, Supplement No. 5, Supplement No. 6, Supplement No. 7, Supplement No. 8, Supplement No. 9,
Supplement No. 10, Supplement No. 11, Supplement No. 12, Supplement No. 13, and Supplement No. 14, the Supplements), which form a part of our Registration Statement on Form S-1 (Registration No. 333-187508).
This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with the information contained in our current report on Form 8-K, filed with the Securities and Exchange Commission (the
Commission) on February 18, 2014 (the Current Report). Accordingly, we have attached the Current Report to this prospectus supplement.
The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series A Convertible
Preferred Stock (Preferred Stock) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants.
This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This prospectus supplement updates and
supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the information in this prospectus
supplement.
Our common stock is traded on the Nasdaq Global Market under the trading symbol ABIO. On February 18, 2014,
the last reported sale price of our common stock was $1.79 per share.
Investing in
our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading Risk Factors beginning on page 5 of the Prospectus and beginning on page 23 of our quarterly report on
Form 10-Q for the quarterly period ended September 30, 2013 before you decide whether to invest in shares of our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.
The date of
this prospectus supplement is February 18, 2014
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 18, 2014 (February 11, 2014)
ARCA biopharma, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-22873
|
|
36-3855489
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
11080 CirclePoint Road, Suite 140, Westminster, CO 80020
(Address of Principal Executive Offices) (Zip Code)
(720) 940-2200
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On February 11, 2014, the Board of Directors (the Board) of
ARCA biopharma, Inc. (the Company) elected Daniel J. Mitchell as a director of the Company to fill a vacancy on the Board.
In
connection with Mr. Mitchells appointment, and pursuant to the Companys previously adopted director compensation policy, the Company granted Mr. Mitchell options to purchase (i) 7,079 shares of common stock (Grant
1) and (ii) 16,000 shares of common stock (Grant 2), each at an exercise price of $1.80 per share, the closing price of the Companys common stock on February 11, 2014. The options are subject to the terms and
conditions of the Companys 2013 Equity Incentive Plan, as amended (the Plan), and the Companys standard forms of Stock Option Agreement and Option Grant Notice for the Plan, copies of which were filed as Exhibit 10.4 to the
Companys Current Report on Form 8-K filed on September 23, 2013. The Grant 1 options vest in equal monthly installments over an eleven month period beginning February 1, 2014, and the Grant 2 options vest in equal monthly
installments over a three year period beginning on the date of grant, in each case assuming Mr. Mitchells continued service on the Board for such periods. On the same date, the Company also approved paying compensation to its existing
non-employee directors by granting to Dr. Linda Grais, Mr. Robert Conway and Dr. Raymond Woosley options to purchase 8,000 shares of common stock at an exercise price of $1.80 per share, the closing price of the Companys common
stock on February 11, 2014. The options are subject to the terms and conditions of the Plan and the Companys standard forms of Stock Option Agreement and Option Grant Notice for the Plan. The options vest in equal monthly installments and
will be fully vested as of December 31, 2014, assuming Dr. Grais, Mr. Conways and Dr. Woosleys continued service on the Board for such periods.
Item 5.08. Shareholder Director Nominations.
On February 11, 2014, the Board approved June 5, 2014 as the date of the Companys Annual Meeting of Stockholders (the
Annual Meeting). The Board also approved April 7, 2014 as the record date for stockholders entitled to notice of and to vote at the Annual Meeting.
Because the Annual Meeting will be held more than 30 calendar days from the date of the Companys 2013 Annual Meeting of Stockholders,
the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the SEC) and the bylaws of the Company listed in the Companys
2013 Proxy Statement on Schedule 14A as filed with the SEC on August 1, 2013 are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no earlier than March 7, 2014 and no
later than April 6, 2014. The Company currently intends to make its proxy materials available beginning on or about April 15, 2014.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: February 18, 2014
|
|
|
ARCA biopharma, Inc.
(Registrant)
|
|
|
By:
|
|
/s/ Christopher D. Ozeroff
|
|
|
Name: Christopher D. Ozeroff
|
|
|
Title: SVP and General Counsel
|
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2024 to May 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From May 2023 to May 2024